|
FEINGOLD SYNDROME 1
|
0.710 |
Biomarker
|
disease |
BEFREE |
These results indicate that while individuals with deletions of 2p spanning several megabases and including MYCN can present with features not typically associated with FS1, the common core features are usually present.
|
30088856 |
2018 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Accordingly, INSM1 has emerged as a critical player closely associated with N-Myc in facilitating NB cell growth.
|
30755485 |
2019 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
These miRNAs were able to suppress endogenous N-myc protein in a MYCN-amplified neuroblastoma cell line.
|
21654684 |
2011 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
This study defines a set of critical dependency genes in MYCN-amplified neuroblastoma that are essential for cell state and survival in this tumor.
|
30127528 |
2018 |
|
Neuroblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
|
12800187 |
2003 |
|
Neuroblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We constructed the subset-specific oligo-capping cDNA libraries from the primary NBL tissues with favorable (F: stage 1, high expression of TrkA and a single copy of MYCN) and unfavorable (UF: stage 3 or 4, decreased expression of TrkA and MYCN amplification) characteristics and randomly cloned 4654 cDNAs.
|
12934113 |
2003 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We established NB xenograft models in non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice with MYCN-amplified SK-N-DZ (DZ) cells or MYCN-non-amplified SK-N-AS (AS) cells.
|
27183205 |
2016 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
As N-Myc amplification correlates with aggressive neuroblastoma and chemotherapy-based treatment failure, co-treatment with cathepsin inhibitors might be a better avenue for disease management.
|
25883214 |
2015 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma.
|
17449239 |
2007 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The presence of 3p, 11q or 14q deletions defines a genetic subset of neuroblastomas and contributes to the further genetic characterization of stage 3 and 4 tumors without MYCN amplification (MNA) and 1p deletion.
|
9739017 |
1998 |
|
Neuroblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Gene expression analysis using TaqMan low-density arrays of 129 primary human neuroblastomas without MYCN amplification revealed that high-level expression of TAM-specific genes (CD14, CD16, IL6, IL6R, and TGFB1) was associated with poor 5-year event-free survival.
|
19411762 |
2009 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
These data suggest that high-level expression of EPHB6, EFNB2, and EFNB3 is associated with favorable NB and that low-level expression of EPHB6, EFNB2, and EFNB3 correlates with aggressive MYCN-amplified NB.
|
10389937 |
1999 |
|
Neuroblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Additionally, the previously reported LMO1 neuroblastoma risk locus was statistically significant only in patients with MYCN-nonamplified high-risk tumors (OR = 0.63, 95% CI = 0.53 to 0.75, Pmeta = 1.51 × 10-8; Pmeta = .95).
|
29117357 |
2017 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The most widely used genetic model for preclinical testing of neuroblastoma is the TH-MYCN mouse.
|
21559450 |
2011 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The potent preclinical activity of CCT137690 suggests that this inhibitor may benefit patients with MYCN-amplified neuroblastoma.
|
21885865 |
2011 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.
|
15571958 |
2004 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In addition, mRNA expression levels of ODC, OAZ2 and MYCN in a MYCN-inducible NB cell line were determined by quantitative real-time reverse-transcriptase polymerase chain reaction (RT-PCR).
|
19960435 |
2010 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Clustering of neuroblastoma cell lines on the basis of hypermethylation distinguished lines with MYCN amplification (a negative prognostic factor) from those without it (P =.012).
|
15316056 |
2004 |
|
Neuroblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In the presence of ALK<sup>F1174L</sup> signaling, MYCN induces the expression of the ubiquitin ligase SKP2 (S-phase kinase-associated protein 2), which targets p27 for degradation and is also upregulated in high-risk NB.
|
27707976 |
2016 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Tumor stage, age of patient, and amplification of MYCN predict disease outcome in neuroblastoma.
|
12450793 |
2002 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We also discuss the subtype of retinoblastoma driven by the MYCN oncogene more commonly associated with neuroblastoma, and consider trilateral retinoblastoma, in which an intracranial tumor arises along with ocular tumors in patients with germline RB1 gene mutations.
|
29314142 |
2019 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Rapid detection of MYCN gene amplification in neuroblastomas using the polymerase chain reaction.
|
1342970 |
1992 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The data are consistent with MYCN influencing neuroblastoma outcome by regulating MRP gene expression.
|
9516823 |
1997 |
|
Neuroblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Targeted ALK(F1174L) and MYCN coexpression revealed a strong synergism in inducing neuroblastoma with minimal chromosomal aberrations, suggesting that fewer secondary hits are required for tumor induction if both oncoproteins are targeted.
|
22764207 |
2012 |
|
Neuroblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
MYC and MYCN control the expression of PD-L1 in neuroblastoma cells both <i>in vitro</i> and <i>in vivo</i> Consistently, abundance of PD-L1 transcript correlates with MYC expression in primary neuroblastoma.<b>Conclusions:</b> The combination of PD-L1 and HLA class I represents a novel prognostic biomarker for neuroblastoma.
|
28270499 |
2017 |